Our Client is a clinical stage, VC backed medical technology company headquartered in Wavre, Belgium. Based on its innovative, proprietary material, our Client has developed a pipeline of next-
generation micro-invasive glaucoma systems (MIGS), addressing issues encountered with currently marketed MIGS devices. Glaucoma is the second leading cause of adult blindness globally.
MIGS represent the most promising and fastest-growing therapeutic option in the treatment of glaucoma. The Clinical